REVENUES

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

REVENUES

REVENUES

Disaggregation of Revenues

The following table summarizes our Total revenues:

	Year Ended December 31, 2023								Year Ended December 31, 2022								Year Ended December 31, 2021
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product sales:
HIV
Biktarvy	$	9,692	$	1,253	$	905	$	11,850	$	8,510	$	1,103	$	777	$	10,390	$	7,049	$	969	$	606	$	8,624
Complera/Eviplera	47		70		12		129		74		113		13		200		102		142		14		258
Descovy	1,771		100		114		1,985		1,631		118		123		1,872		1,397		164		139		1,700
Genvoya	1,752		205		103		2,060		1,983		284		136		2,404		2,267		391		221		2,879
Odefsey	1,012		294		44		1,350		1,058		364		47		1,469		1,076		440		52		1,568
Stribild	72		21		8		101		88		29		10		127		132		43		14		189
Truvada	82		13		19		114		113		15		18		147		314		22		35		371
Revenue share - Symtuza(1)	382		133		13		529		348		168		14		530		355		165		11		531
Other HIV(2)	37		12		7		56		15		24		17		57		136		30		29		195
Total HIV	14,848		2,102		1,226		18,175		13,820		2,219		1,155		17,194		12,828		2,366		1,121		16,315
Oncology
Cell Therapy
Tecartus	245		110		15		370		221		75		3		299		136		40		—		176
Yescarta	811		547		140		1,498		747		355		57		1,160		406		253		36		695
Total Cell Therapy	1,055		658		156		1,869		968		430		60		1,459		542		293		36		871
Trodelvy	777		217		68		1,063		525		143		12		680		370		10		—		380
Total Oncology	1,833		875		224		2,932		1,494		573		73		2,139		912		303		36		1,251
Liver Disease
Chronic hepatitis C virus (“HCV”)
Ledipasvir/ Sofosbuvir(3)	39		12		19		70		46		17		51		115		84		31		97		212
Sofosbuvir/Velpatasvir(4)	859		323		355		1,537		844		355		331		1,530		815		316		331		1,462
Other HCV(5)	104		43		12		160		115		40		10		166		119		74		14		207
Total HCV	1,002		378		386		1,767		1,005		413		392		1,810		1,018		421		442		1,881
Chronic hepatitis B virus (“HBV”) / Chronic hepatitis delta virus (“HDV”)
Vemlidy	410		38		414		862		429		35		379		842		384		34		396		814
Viread	8		22		52		83		6		23		62		91		11		28		72		111
Other HBV/HDV(6)	—		72		—		72		—		55		—		55		2		42		—		44
Total HBV/HDV	418		133		466		1,017		435		112		441		988		397		104		468		969
Total Liver Disease	1,421		511		852		2,784		1,440		525		833		2,798		1,415		525		910		2,850
Veklury	972		408		805		2,184		1,575		702		1,628		3,905		3,640		1,095		830		5,565
Other
AmBisome	43		260		189		492		57		258		182		497		39		274		227		540
Letairis	142		—		—		142		196		—		—		196		206		—		—		206
Other(7)	118		40		66		225		135		65		53		253		136		115		30		281
Total Other	304		301		255		859		388		323		235		946		381		389		257		1,027
Total product sales	19,377		4,197		3,361		26,934		18,716		4,342		3,924		26,982		19,176		4,678		3,154		27,008
Royalty, contract and other revenues	62		114		7		182		168		127		4		299		91		196		10		297
Total revenues	$	19,438	$	4,310	$	3,368	$	27,116	$	18,884	$	4,469	$	3,928	$	27,281	$	19,267	$	4,874	$	3,164	$	27,305

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 7. Collaborations and Other Arrangements for additional information.

(2)    Includes Atripla, Emtriva, Sunlenca and Tybost.

(3)    Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)    Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)    Includes Vosevi and Sovaldi.

(6)    Includes Hepcludex and Hepsera.

(7)    Includes Cayston, Jyseleca, Ranexa and Zydelig.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:

	Year Ended December 31,
(as a percentage of total revenues)	2023		2022		2021
Cardinal Health, Inc.	26	%	25	%	22	%
Cencora, Inc. (formerly known as AmerisourceBergen Corporation)	19	%	18	%	23	%
McKesson Corporation	21	%	20	%	20	%

Revenues Recognized from Performance Obligations Satisfied in Prior Years

The following table summarizes revenues recognized from performance obligations satisfied in prior years:

	Year Ended December 31,
(in millions)	2023		2022		2021
Revenue share with Janssen(1) and royalties for licenses of intellectual property	$	680	$	783	$	851
Changes in estimates	$	340	$	582	$	856

________________________________

(1)    See Note 7. Collaborations and Other Arrangements for additional information.

Contract Balances

The following table summarizes our contract balances:

	December 31,
(in millions)	2023		2022
Contract assets(1)	$	117	$	171
Contract liabilities(2)	$	109	$	102

________________________________

(1)    Consists of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation.

(2)    Generally results from receipt of advance payment before our performance under the contract.